Key result
Antibodies to citrullinated peptide antigens (ACPA) positivity strongly predicted the development of joint erosions in patients with rheumatoid arthritis (OR 4.85).
Why the study?
Does ACPA positivity predict the development of joint erosions in patients with rheumatoid arthritis?
Population
6,421 patients with rheumatoid arthritis (RA) from 25 studies, mainly in inception cohorts
Comparison
Positivity for antibodies to citrullinated… vs ACPA negativity
Design
Meta-analysis
Follow-up
1 to 10 years
Authors
Loading...
Supports ACPA testing for erosive risk stratification in RA; confirms strong prognostic value across studies.
Meta-Analysis (n=6,421)
Does ACPA positivity predict the development of joint erosions in patients with rheumatoid arthritis?
Odds Ratio: 4.85
ACPA positivity is a strong predictor of joint erosions in rheumatoid arthritis, with an odds ratio of 4.85, supporting its use as a prognostic marker in routine practice.
Jilani et al. (2015) conducted a meta-analysis in Rheumatoid Arthritis (n=6,421). Antibodies to citrullinated peptide antigens (ACPA) was evaluated on development of joint erosions (OR 4.85). Antibodies to citrullinated peptide antigens (ACPA) positivity strongly predicted the development of joint erosions in patients with rheumatoid arthritis (OR 4.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: